Repeated central administration of selegiline attenuated morphine physical dependence in rat. 2013

Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

BACKGROUND Long-term exposure to opiates induces physical dependence; however, the neurobiological mechanisms of this phenomenon are not completely clear. The purpose of this study was to evaluate the effects of systemic and intracerebroventricular (icv) administration of selegiline (a selective inhibitor of monoamine oxidase B) on the morphine withdrawal syndrome in rats. METHODS To this aim, adult male Sprague Dawley rats were selected randomly, and then growing doses of morphine were administered subcutaneously at an interval of 12 h for nine days with the intention of inducing dependency. Nine days after, only the morning dose of morphine was administered, followed by systemic or central injection of saline or selegiline. Later, naloxone was injected after 30 min and withdrawal signs recorded for a period of 60 min. RESULTS Results showed failure of systemic administration of selegiline in changing the withdrawal symptoms; nevertheless, icv injection attenuated the withdrawal signs significantly. CONCLUSIONS In conclusion we found that central administration of selegiline attenuated morphine withdrawal symptoms.

UI MeSH Term Description Entries
D008297 Male Males
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009021 Morphine Dependence Strong dependence, both physiological and emotional, upon morphine. Morphine Abuse,Morphine Addiction,Abuse, Morphine,Addiction, Morphine,Dependence, Morphine
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012642 Selegiline A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. Deprenalin,Deprenil,Deprenyl,E-250,Eldepryl,Emsam,Humex,Jumex,L-Deprenyl,Selegiline Hydrochloride,Selegiline Hydrochloride, (R)-Isomer,Selegiline Hydrochloride, (R,S)-Isomer,Selegiline Hydrochloride, (S)-Isomer,Selegiline, (R)-Isomer,Selegiline, (R,S)-Isomer,Selegiline, (S)-Isomer,Selegyline,Yumex,Zelapar,E 250,E250
D013375 Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. Drug Withdrawal Symptoms,Withdrawal Symptoms,Drug Withdrawal Symptom,Substance Withdrawal Syndromes,Symptom, Drug Withdrawal,Symptom, Withdrawal,Symptoms, Drug Withdrawal,Symptoms, Withdrawal,Syndrome, Substance Withdrawal,Syndromes, Substance Withdrawal,Withdrawal Symptom,Withdrawal Symptom, Drug,Withdrawal Symptoms, Drug,Withdrawal Syndrome, Substance,Withdrawal Syndromes, Substance
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
November 2014, International journal of preventive medicine,
Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
May 2015, Iranian journal of medical sciences,
Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
December 1983, Japanese journal of pharmacology,
Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
January 1974, Pharmacology,
Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
March 1982, British journal of pharmacology,
Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
August 1972, Nature,
Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
February 2008, Pharmacology, biochemistry, and behavior,
Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
April 1973, British journal of pharmacology,
Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
November 1978, Drug and alcohol dependence,
Alireza Parvizpour, and Mohammad Charkhpour, and Bohlool Habibi-asl, and Mobin Shakhsi, and Majid Ghaderi, and Kambiz Hassanzadeh
March 1960, Archives internationales de pharmacodynamie et de therapie,
Copied contents to your clipboard!